Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M629Revenue $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M629EPS $--Operating Margin %--Piotroski F-Score--
P/E(ttm)18.4Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book5.710-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %0.3PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M6,096,503ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with BBH

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

BBH is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


BBH: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Dubuc, PhilippeSenior Officer 2016-04-08Buy1,700$1.995086.93view
Dubuc, PhilippeSenior Officer 2016-04-08Buy3,300$25061view
PAMPLIN, Ann-Marie MichelleDeemed Insider - 6 Months before becoming Insider 2016-04-08Buy10,000$0.1568713.33view
Williams, Allan WilliamSenior Officer 2016-04-08Buy108,500$0.1193736.36view
Stefura, Naomi MarieSenior Officer 2016-04-08Sell4,200$14.6606.99view
Gentiletti, NelsonDirector or Senior Officer of Insider or Subsidiar 2016-04-08Sell800$20.78396.73view
Gentiletti, NelsonDirector or Senior Officer of Insider or Subsidiar 2016-04-08Sell400$20.77396.97view
Gentiletti, NelsonDirector or Senior Officer of Insider or Subsidiar 2016-04-08Sell300$20.75397.45view
Gentiletti, NelsonDirector or Senior Officer of Insider or Subsidiar 2016-04-08Sell100$20.72398.17view
Gentiletti, NelsonDirector or Senior Officer of Insider or Subsidiar 2016-04-08Sell900$20.7398.65view

Quarterly/Annual Reports about BBH:

    News about BBH:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    A Promising Uptake for Vertex’s Orkambi May 04 2016
    Biotech ETFs Sink on Mixed Q1 Results May 02 2016
    2 Dirt-Cheap Big Pharma Stocks Poised to Beat Biotech's Bad Rap May 02 2016
    Why Is Medivation at a Premium on an EV-to-EBITDA Basis? Apr 14 2016
    A Rare Opportunity With A Biotechnology ETF Mar 17 2016
    Is The Biotech Bear Market Over? Feb 29 2016
    6 Top-Ranked ETFs to Rebound on Bargain Hunt Feb 25 2016
    Some Traders Aren't Shy About Betting On A Biotech Rebound Feb 19 2016
    Biotech ETFs Slide as Stocks Report Mixed Q4 Results Feb 09 2016
    Tracking The Biotech Bubble's Bust Jan 31 2016
    Celgene’s Valuation Is Higher Than Its Peers Jan 25 2016
    What Are Analysts’ Expectations for BioMarin? Jan 19 2016
    New ETF Is A Refined Pharmaceuticals Play Jan 14 2016
    Van Eck Launches Market Vectors® Generic Drugs ETF (GNRX) Jan 13 2016
    Bristol-Myers CEO: Looking forward to 2016 Jan 12 2016
    BioMarin CEO on drug pricing, approval Jan 12 2016
    Alex Denner on biotech selloff Jan 12 2016
    Pricing drug innovation Jan 12 2016
    JNJ CEO: Seen some near-term slowdown in China Jan 11 2016
    JNJ CEO: Long-term view on biotech & devices Jan 11 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)